Tesamorelin 10mg/20mg

What is Tesamorelin?

Tesamorelin is a synthetic peptide that acts as an analogue of the growth hormone–releasing hormone (GHRH). It stimulates the pituitary gland to release growth hormone (GH), which leads to increased levels of IGF-1 in the body.

Unlike the direct administration of growth hormone, tesamorelin activates the body’s natural mechanisms. It works “upstream”, by stimulating the hypothalamus–pituitary regulatory axis and preserving the physiological pulsatile pattern of GH secretion. This means better control, a lower risk of excessive stimulation, and a more physiological hormonal response.

After binding to the GHRH receptors, the cAMP signalling pathway is activated, leading to increased GH release and a subsequent rise in IGF-1 via a natural mechanism.

Tesamorelin was developed by Theratechnologies and has been approved for medical use since 2010 for HIV-associated lipodystrophy—a condition characterised by the accumulation of visceral fat.

The peptide stands out for its clearly targeted effect on visceral fat tissue, making it one of the few GHRH analogues with real clinical use and a strong scientific foundation.

What are the benefits of Tesamorelin?

Tesamorelin is a peptide with a clearly defined profile and well-documented effects in studies on metabolism and body composition.

• Reducing visceral fat

This is the primary and best-supported effect. The peptide leads to a significant reduction in deep abdominal fat, which is associated with insulin resistance and cardiovascular risk.

• Stimulating the body’s natural release of growth hormone

Tesamorelin increases GH and IGF-1 via a physiological pathway, preserving natural regulation and feedback in the body.

• Improving metabolic balance

Through its action on the GH axis, the peptide influences how the body uses energy and manages fat depots.

• Improving the lipid profile

Studies show a reduction in triglycerides and improvement in some lipid markers.

• Effect on liver fat

There is evidence that tesamorelin may reduce fat accumulation in the liver, which makes it particularly interesting in studies on NAFLD.

• Improving body composition

It combines fat reduction with relatively preserved non-fat tissue, which is key in long-term protocols.

• More physiological GH control

Unlike direct GH or some GHRP peptides, tesamorelin does not lead to sudden and uncontrolled hormonal stimulation.

Clinical trials on Tesamorelin

Tesamorelin is one of the few peptides with real clinical data in humans and published results in reputable scientific sources.

In a key study published in The New England Journal of Medicine, a significant reduction in visceral adipose tissue was observed in HIV patients after 26 weeks of treatment.

Key results:

approximately 15 to 20 per cent reduction in visceral fat, a significant increase in IGF-1, and improvement in metabolic markers.

In subsequent studies, the effect is maintained for up to 52 weeks, with a greater reduction in visceral than in subcutaneous fat.

Additional research published in the Journal of Clinical Endocrinology & Metabolism shows that tesamorelin preserves the natural pulsatility of GH, which explains its physiological effect.

In JAMA, data have been published on effects on liver fat, where a reduction in fat accumulation was observed in specific populations.

These findings position tesamorelin as one of the best-studied GHRH analogues, with a clearly defined effect on metabolism and adipose tissue.

Correct use and dosage of Tesamorelin within a research protocol

Tesamorelin is administered by subcutaneous injection once daily. A standard research dose is in the range of 0.5 to 2 mg per day.

Most often it is given in the evening, before sleep, and no less than two hours after eating, and especially after carbohydrate intake. The reason for evening administration is related to the natural GH peak during sleep and better synchronisation with physiology.

In some protocols, morning administration on an empty stomach may be acceptable, depending on the study objectives.

The protocol duration varies from 12 to 24 weeks. The break between cycles is from 4 to 8 weeks.

Possible side effects of Tesamorelin

As with all peptides, reactions are individual and most often dose-dependent.

Most common:

• redness or irritation at the injection site
• mild swelling
• fluid retention
• joint pain
• muscle discomfort

Less common:

• numbness in the extremities
• slight increase in blood sugar
• headache

In most cases, side effects are temporary and decrease as your body adapts to the protocol.

The information on this website has been compiled and summarised from multiple scientific studies and analyses.

It is provided for informational purposes only and is not intended for diagnosing, treating, or preventing diseases.

The products offered on the site are not classified as medicines or medical devices and are intended solely for laboratory and research purposes.

Check the authenticity of this certificate through the official website of the independent laboratory Analiza Bialek.